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ABSTRACT
Objective: To assess volumes and microstructural integrity of deep gray matter structures in
a homogeneous cohort of patients with neuromyelitis optica spectrum disorder (NMOSD).
Methods: This was a cross-sectional study including 36 aquaporin-4 antibody-positive (AQP4
Ab-positive) Caucasian patients with NMOSD and healthy controls matched for age, sex, and edu-
cation. Volumetry of deep gray matter structures (DGM; thalamus, caudate, putamen, globus
pallidus, hippocampus, amygdala, nucleus accumbens) was performed using 2 independent auto-
mated methods. Microstructural integrity was assessed based on diffusion tensor imaging.
Results: Both volumetric analysis methods consistently revealed similar volumes of DGM struc-
tures in patients and controls without significant group differences. Moreover, no differences
in DGM microstructural integrity were observed between groups.
Conclusions: Deep gray matter structures are not affected in AQP4 Ab-positive Caucasian pa-
tients with NMOSD. NMOSD imaging studies should be interpreted with respect to Ab status,
educational background, and ethnicity of included patients. Neurol Neuroimmunol Neuroinflamm
2016;3:e229; doi: 10.1212/NXI.0000000000000229
GLOSSARY
Ab 5 antibody; AQP4 5 aquaporin-4; DGM 5 deep gray matter; DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy;
ICV 5 intracranial volume; LETM 5 longitudinally extensive transverse myelitis; MANOVA 5 multivariate analysis of vari-
ance; MD 5 mean diffusivity; MOG 5 myelin oligodendrocyte glycoprotein; NMO 5 neuromyelitis optica; NMOSD 5 neuro-
myelitis optica spectrum disorder; ON 5 optic neuritis.
Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune CNS conditions that are
associated with antibodies (Abs) targeting astrocytic aquaporin-4 (AQP4) water channels in the
majority of patients.1 Hallmark clinical symptoms are optic neuritis (ON) and longitudinally
extensive transverse myelitis (LETM), but other clinical symptoms, mostly brainstem-associated,
might also be present.2 Accordingly, clinical routine MRI can show edema of the optic nerve and
longitudinally extensive spinal cord lesions, but also—mostly nonspecific—cerebral white matter
lesions.3 Imaging studies using diffusion tensor imaging (DTI) or ultra-high-field MRI have
revealed white matter damage predominantly affecting the visual pathway and the corticospinal
tract. Results regarding abnormalities of deep gray matter (DGM) structures are inconsistent,
with some studies reporting normal volumes while other studies observed hippocampal and
thalamic atrophy. These conflicting results might be driven by differences between studies or
heterogeneity within patient cohorts regarding sample size, ethnicity, educational background,
Ab status, and applied imaging analysis methods. We therefore studied DGM structures in
a large, well-characterized cohort of AQP4 Ab–positive Caucasian patients with NMOSD ful-
filling the latest diagnostic criteria.2 First, we used the 2 most established tools (FSL FIRST and
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Freesurfer) to perform automated volumetric
analyses of DGM structures. Second, we ana-
lyzed DGM microstructural integrity using
DTI.
METHODS Patients and controls. For this cross-sectional
observational study, 36 patients fulfilling the 2015 international
consensus diagnostic criteria for NMOSD2 were recruited from
the outpatient clinics of the NeuroCure Clinical Research Center
and the Department of Neurology of Charité-Universitätsmedizin
Berlin (table). All patients were tested for the presence of AQP4 and
myelin oligodendrocyte glycoprotein (MOG) Abs by an accredited
clinical laboratory (Euroimmun, Lübeck, Germany). Inclusion
criteria were Caucasian ethnicity and AQP4 Ab seropositivity.
Patients with MOG Abs were excluded. The majority of patients
(17 of 36; 47%) were characterized by the classic neuromyelitis
optica phenotype (ON 1 acute myelitis/LETM). Two patients
exhibited a history of area postrema syndrome in addition to
ON/myelitis. Another 2 patients had a history of acute brainstem
syndrome concomitant with ON and LETM. Other patients were
characterized by isolated or recurrent ON without other symptoms
(5), LETM alone (8), and combinations of LETM and acute
brainstem syndrome (1) and LETM with area postrema
syndrome and acute brainstem syndrome (1). All but one of the
patients with NMOSD were treated with immunosuppressive
therapy at the time of investigation (rituximab, 17; azathioprine,
12; mycophenolate mofetil, 2; methotrexate, 1; glatiramer acetate
1; stand-alone prednisolone treatment, 1; plasmapheresis, 1). Seven
patients had add-on oral prednisolone therapy. All patients were
relapse-free and without high-dose corticosteroid treatment at least
2 weeks prior to the MRI investigations.
The control group comprised 36 healthy participants from
the NeuroCure Clinical Research Center research database who
had no history of neurologic or psychiatric diseases and who were
matched for age, sex, and years of education (table).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional review
board of the Charité-Universitätsmedizin Berlin. All study par-
ticipants gave written informed consent.
MRI data acquisition. MRI data were acquired on a Siemens
Magnetom Tim Trio 3T scanner (Siemens, Erlangen, Germany)
using previously described sequences4: (1) a high-resolution 3D
magnetization-prepared rapid gradient-echo sequence (voxel size
1 3 1 3 1 mm3) and (2) a single-shot echoplanar imaging
sequence for the acquisition of DTI data (available for 31
patients and 24 controls).
Analysis of subcortical volumes and microstructural
integrity. Analyses were performed as described previously.4
We used the 2 most established and most commonly applied
tools to analyze subcortical volumes to account for possible meth-
odologic differences between previous studies, i.e., FSL FIRST
(v5.0.0) and Freesurfer (v5.1). FSL FIRST performs subcortical
registration and segmentation using Bayesian shape and appear-
ance models constructed from manually segmented images.5 Vol-
umetric segmentation with Freesurfer includes removal of
nonbrain tissue using a hybrid watershed/surface deformation
procedure and automated Talairach transformation followed by
segmentation of the deep gray matter volumetric structures.6 In
both analyses, left and right volumes of DGM structures were
averaged. Volumes of all subcortical structures in both analysis
pipelines were adjusted for intracranial volume (ICV) by using
the following formula:
Volumeadjusted5Volumeobserved
2bðslope from ICV vs regional volume regressionÞ
3

ΙCVobserved2 ICVsample mean

Microstructural integrity of DGM structures was assessed by
DTI using FSL 4.1. After preprocessing, individual fractional
anisotropy (FA) and mean diffusivity (MD) maps were calculated
by fitting a tensor model to the diffusion data. FA and MD maps
were registered to the brain-extracted T1-weighted images. Indi-
vidual mean MD and FA values of DGM structures were calcu-
lated based on DGM masks obtained with FSL FIRST.
Statistical analysis. Statistical analyses were performed using
SPSS 22 (IBM, Armonk, NY). Demographic variables were com-
pared between groups using independent samples t tests. To
compare subcortical volumes between patients and controls, mul-
tivariate analyses of variance (MANOVA) with group as factor
and the 7 DGM structure volumes as dependent variables were
performed. Additionally, MANOVAs were repeated with age,
sex, and years of education as covariates.
RESULTS Both volumetric analysis pipelines revealed
normal deep gray matter volumes in AQP4 Ab-positive
patients with NMOSD in comparison to healthy
controls matched for age, sex, and years of education
(table, figure 1). For both analyses, observed effect
sizes (partial ƞ2) were very low, ranging from ,0.001
to 0.032. No significant differences in microstructural
integrity were observed between patients and controls
for any of the investigated DGM structures (table,
figure 2). Similarly, effect sizes were very low (partial
ƞ2 ,0.001–0.046). Repeated analyses with age, sex,
and years of education showed similar results without
significant differences between patients and controls
and low effect sizes throughout for all volumetric and
microstructural integrity measures.
DISCUSSION We found normal volumes and micro-
structural integrity of DGM structures in AQP4 Ab-
positive Caucasian patients with NMOSD. Given
the homogeneity of the investigated patient cohort
and the application of 2 independent automatic
volumetric methodologic approaches as well as
additional DTI analyses, these results might help to
interpret inconsistent findings in the neuromyelitis
optica (NMO)/NMOSD imaging literature.
As a key point of this study, several measures were
taken to establish a homogeneous study cohort and to
assess the effect of different analysis methods.
First, the current study was restricted to Caucasian
patients withNMOSD given that ethnicity likely inter-
acts with NMOSD pathogenicity, as indicated by a dis-
proportionate affection of Asian and African American
populations. Second, patients and controls were care-
fully matched with respect to age, sex, and educational
background since all 3 variables have been shown to
interact with DGM volume, and analyses were addi-
tionally performed using the parameters as covariates.
Third, only AQP4 Ab-positive patients were recruited.
AQP4 Ab-positive and -negative patients may exhibit
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distinct disease patterns and a subset of seronegative pa-
tients harbor MOG Abs that may be associated with
a distinct clinical entity.1 Fourth, volumetric analyses
were performed using the 2 most established software
packages that have previously been used in NMO
research, i.e., FSL FIRST and Freesurfer, to account
Table Demographic information of patients and controls and volumes, mean diffusivity, and fractional
anisotropy of deep gray matter structures
Patients with NMOSD Healthy controls p Value Partial ƞ2
Age, y, mean 6 SD 47.9 6 15.2 45.4 6 15.4 0.491a
Sex, F/M 34/2 34/2 NA
Years of education, mean 6 SD 14.2 6 3.1 14.4 6 2.5 0.726a
AQP4 Ab, positive/negative 36/0 NA —
Disease duration, y, mean 6 SD 9.09 6 10.0 NA —
EDSS score, median (range) 4.0 (1–6.5) NA —
FSL FIRST NDGMV, mm3
Thalamus 7,418.3 6 582.0 7,411.9 6 609.9 0.964b ,0.001
Caudate nucleus 3,313.5 6 394.0 3,367.5 6 439.9 0.584 0.004
Putamen 4,620.7 6 566.4 4,626.7 6 455.2 0.960 ,0.001
Globus pallidus 1,712.7 6 197.9 1,768.9 6 307.0 0.359 0.012
Hippocampus 3,810.4 6 368.1 3,726.1 6 402.8 0.357 0.012
Amygdala 1,348.2 6 186.8 1,317.2 6 164.8 0.458 0.008
Nucleus accumbens 406.8 6 78.8 402.5 6 76.8 0.813 0.001
Freesurfer NDGMV, mm3
Thalamus 6,691.1 6 671.4 6,822.3 6 700.5 0.420b 0.009
Caudate nucleus 3,341.1 6 392.4 3,379.4 6 476.7 0.711 0.002
Putamen 4,989.5 6 666.5 5,004.0 6 660.4 0.927 ,0.001
Globus pallidus 1,534.1 6 196.3 1,601.7 6 178.2 0.130 0.032
Hippocampus 3,971.8 6 365.5 4,009.9 6 385.3 0.669 0.003
Amygdala 1,398.3 6 165.6 1,399.4 6 168.2 0.977 ,0.001
Nucleus accumbens 497.1 6 98.7 532.8 6 125.9 0.185 0.025
Fractional anisotropy
Thalamus 0.321 6 0.021 0.314 6 0.014 0.182b 0.033
Caudate nucleus 0.184 6 0.027 0.173 6 0.028 0.148 0.039
Putamen 0.222 6 0.019 0.218 6 0.022 0.444 0.011
Globus pallidus 0.389 6 0.056 0.361 6 0.074 0.117 0.046
Hippocampus 0.142 6 0.018 0.142 6 0.014 0.839 0.001
Amygdala 0.172 6 0.023 0.170 6 0.017 0.683 0.003
Nucleus accumbens 0.301 6 0.054 0.288 6 0.058 0.426 0.012
Mean diffusivity, 1023 mm2/s
Thalamus 0.804 6 0.053 0.812 6 0.037 0.563b 0.006
Caudate nucleus 1.213 6 0.176 1.290 6 0.245 0.180 0.034
Putamen 0.732 6 0.052 0.734 6 0.037 0.908 ,0.001
Globus pallidus 0.694 6 0.053 0.715 6 0.067 0.190 0.032
Hippocampus 1.011 6 0.060 0.997 6 0.069 0.457 0.010
Amygdala 0.935 6 0.114 0.907 6 0.077 0.306 0.020
Nucleus accumbens 0.722 6 0.059 0.746 6 0.075 0.200 0.031
Abbreviations: Ab 5 antibody; AQP4 5 aquaporin-4; EDSS 5 Expanded Disability Status Scale; NA 5 not applicable;
NDGMV 5 normalized deep gray matter volume; NMOSD 5 neuromyelitis optica spectrum disorder.
DTI data (FA and MD) were available for 31 patients and 24 controls.
a Independent samples Student t test.
bMultivariate analysis of variance.
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for possible methodologic differences. In addition,
DTI was used for a sensitive assessment of DGM struc-
tural integrity.
Previous studies that vary along the above dis-
cussed disease dimensions observed conflicting re-
sults. Investigating 18 AQP4-positive patients with
NMO recruited in the United Kingdom, a recent
study found no atrophy of the thalamus using FSL
FIRST.7 In contrast, a study of 54 patients with
NMO (70% AQP4-positive) recruited in China
observed reduced volumes of thalamus, hippocam-
pus, and nucleus accumbens in comparison to healthy
controls.8 While educational background was not re-
ported in the former study, in the latter study healthy
controls had .1 year more formal education than
patients, although the difference was not significant
for all patient subgroups. Importantly, DGM atrophy
was only observed in cognitively impaired patients
but not in cognitively intact patients and in a regres-
sion analysis cognitive impairment was largely driven
by the level of education, which by itself has been
associated with lower DGM volumes.9 A study of
30 patients with NMO (21 Italian, 9 Korean; 83%
AQP4-positive) that used Freesurfer to assess cortical
and deep gray matter found no cortical lesions and
only mild thinning of sensorimotor and visual cortex
as well as mild thalamic atrophy.10 These changes
were interpreted to be caused by retrograde axonal
degeneration due to spinal cord damage.
DTI-derived measures FA and MD of gray matter
structures are sensitive markers of microstructural
integrity and can indicate neuronal damage caused
by microscopic barrier disruption and extracellular
fluid accumulation. Furthermore, these measures
have been shown to differentiate patients from
healthy controls and to correlate with clinical impair-
ment.4 Here, we observed normal DGM microstruc-
tural integrity in patients with NMOSD. Together
with the observation of normal volumes, these results
clearly indicate that DGM structures are not affected
in our patients with NMOSD. Of note, this finding
contrasts with prominent atrophy of deep gray matter
structures in multiple sclerosis and suggests a more
focal brain pathology in NMOSD.11
While the results of this study cannot be general-
ized to all NMOSD cohorts, they provide strong evi-
dence that DGM structures are intact in AQP4
Ab-positive Caucasian patients with NMOSD. Thus,
Figure 1 Deep gray matter volumes
Analysis of deep gray matter volumes with Freesurfer (A) and FSL FIRST (B) in patients with neuromyelitis optica spectrum
disorder (NMOSD) and controls matched for age, sex, and years of education revealed no significant group differences.
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future studies should address imaging differences
between patients with NMOSD along the proposed
dimensions of Ab status, ethnicity, and educational
background and correlate these findings with cogni-
tive performance.12
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